$2.34
0.010.43%
Last update: Nov 9, 4:00 PM
Macrogenics Inc
MGNXNASDAQ
Macrogenics rose 63.6% from $1.43 to $2.34, ahead of the S&P 500's +10.5%. Its worst day was Oct 23 (−38.0%), and its low came Dec 8 at $1.33.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.27 beat the $-0.39 estimate on $72.8M revenue (est. $28.6M).
+8.8% · S&P 500 −1.7%
Macrogenics closed at its lowest level of the year, 7.0% below where the year started.
Story events cover the past 12 months · Times ET
−2.9% · S&P 500 −0.3%
Macrogenics shares rose 19.3%, while the S&P 500 fell 1.1%.
+19.3% · S&P 500 −1.1%
EPS of $-0.22 missed the $-0.18 estimate on $41.2M revenue (est. $26.3M).
+45.3%, the year's best day, on 14M shares, the year's heaviest volume · S&P 500 −0.2%
Macrogenics shares rose 16.1%, while the S&P 500 rose 0.6%.
+16.1% · S&P 500 +0.6%
EPS of $-0.58 missed the $-0.55 estimate on $20.8M revenue (est. $15.9M).
+20.6% · S&P 500 +0.8%
Macrogenics closed at its highest level of the year, 239.9% above where the year started.
+1.0% · S&P 500 +1.6%
EPS of $-0.27 missed the $0.14 estimate on $32.8M revenue (est. $56.1M).
+3.4% · S&P 500 −0.2%
Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN
−38.0%, the year's worst day · S&P 500 −0.5%
Where it ended: a close of $2.34 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.12, revenue est. $43.7M).
Nothing in the past 12 months.
All MGNX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MGNX and SPY from Benzinga historical bars. Not investment advice.
